Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Year: 2016
Type: article
Abstract: We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. Estimates of complete remission (CR) and overall survival (OS) were weighted by the frequency distribution of prognostic factors in the blinatumomab trial. Outcomes were also compared between the trial and historical data using propensity score methods. The historical cohort included 694 patients with CR data and 1112 patients with OS data compared with 189 patients with CR and survival data in the blinatumomab trial. The weighted analysis revealed a CR rate of 24% (95% CI: 20-27%) and a median OS of 3.3 months (95% CI: 2.8-3.6) in the historical cohort compared with a CR/CRh rate of 43% (95% CI: 36-50%) and a median OS of 6.1 months (95% CI: 4.2-7.5) in the blinatumomab trial. Propensity score analysis estimated increased odds of CR/CRh (OR=2.68, 95% CI: 1.67-4.31) and improved OS (HR=0.536, 95% CI: 0.394-0.730) with blinatumomab. The analysis demonstrates the application of different study designs and statistical methods to compare novel therapies for R/R ALL with historical data.
Source: Blood Cancer Journal
DOI: 10.1038/bcj.2016.84
Institutions: Goethe University Frankfurt, University Hospital Frankfurt, Amgen (United States), Cleveland Clinic, Ospedale dell' Angelo, Hôpital Saint-Louis, University Hospital Brno, University College London, The Maria Sklodowska-Curie National Research Institute of Oncology, Amgen (United Kingdom), Centre Hospitalier Universitaire d'Angers, University of Bologna, Josep Carreras Leukaemia Research Institute, Hospital Universitari Germans Trias i Pujol, Rambam Health Care Campus, City Of Hope National Medical Center, City of Hope, University of Würzburg, Universitätsklinikum Würzburg, Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Funder: Amgen
OpenAlex ID: W2521076777
